DMN:FRA
Diamyd Medical AB
€0.063
arrow_downward
-0.63%(-0.00040) 1 天
11月13日, GMT+1 22:00:00 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 DMN 生成关键数据洞见…
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.40亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
开盘价
€0.06
最高价
€0.06
最低价
€0.06
市值
1.40亿
平均成交量
0.00
成交量
0.00
52 周最高价
€1.80
52 周最低价
€0.05
员工人数
42
新闻报道
来自网络来源和新闻合作伙伴
TradingView
·
3小时前
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
The Motley Fool
·
7小时前
Prediction: This Small-Cap Value ETF Will Beat the S&P 500 Over the Next 10 Years
Bloomberg.com
·
8小时前
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
资料
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Diamyd Medical AB简介